Skip to Main Content

Author Details

Robert Aiken
Rutgers Cancer Institute of New Jersey, Rutgers University
1984
25
14
PMIDPaper TitleJournal TitlePublished Year
36394838Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.JAMA Oncol2023
37188783Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.Nat Med2023
36517865Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.J Exp Clin Cancer Res2022
34623599Leptomeningeal disease in glioblastoma: endgame or opportunity?J Neurooncol2021
33771666Oncolytic virus in gliomas: a review of human clinical investigations.Ann Oncol2021
33665625Generation of glioblastoma patient-derived organoids and mouse brain orthotopic xenografts for drug screening.STAR Protoc2021
32169409BRAINSTORM: A Multi-Institutional Phase 1/2 Study of RRx-001 in Combination With Whole Brain Radiation Therapy for Patients With Brain Metastases.Int J Radiat Oncol Biol Phys2020
31118108Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.J Immunother Cancer2019
31320597A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma.Clin Cancer Res2019
29843811First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.J Transl Med2018
29958537Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.J Transl Med2018
28805000A 54-Year-Old Male with Multiple Intracranial and Extracranial Masses.Brain Pathol2017
28331050First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors.Clin Cancer Res2017
29113409Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response.Oncotarget2017
25173136Primary brain tumors: introduction.Semin Oncol2014
25173137Molecular neuro-oncology and the challenge of the blood-brain barrier.Semin Oncol2014
16769424Neurologic complications of head and neck cancers.Semin Oncol2006
15938011Treatment of brain tumors.N Engl J Med2005
12125986An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis.J Neurooncol2002
11161370Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine.Br J Cancer2001
11304771Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas.J Clin Oncol2001
9884301Delayed cortical blindness and recurrent quadriplegia after cervical trauma.J Spinal Disord1998
9414429Regression of C6 rat brain tumors by cells expressing an antisense insulin-like growth factor I receptor RNA.J Exp Ther Oncol1996
8153670Quality-of-life issues in patients with malignant gliomas.Semin Oncol1994
6384434Metronidazole in the treatment of metastatic brain tumors. Results of a controlled clinical trial.J Neurooncol1984
  • 1 - 25 of 25

Recommended Authors

Massachusetts General Hospital Cancer Center, Harvard Medical School
Career Start Year 2013
Number of shared co-authors 1
University of Florida
Career Start Year 2008
Number of shared co-authors 0
McGovern Medical School at UT Health Houston
Career Start Year 2007
Number of shared co-authors 1
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 5
University of California san francisco
Career Start Year 2005
Number of shared co-authors 18
Medical University of Vienna
Career Start Year 2003
Number of shared co-authors 9
University Hospital Essen
Career Start Year 2002
Number of shared co-authors 3
Clinical Sciences Building, The University of Melbourne, The Royal Melbourne Hospital
Career Start Year 2001
Number of shared co-authors 0
University Hospital Tubingen, Eberhard-Karls-University Tubingen
Career Start Year 1998
Number of shared co-authors 13
University of California san francisco
Career Start Year 1997
Number of shared co-authors 9
Lenox Hill Hospital
Career Start Year 1997
Number of shared co-authors 2
0The Alfred Hospital
Career Start Year 1997
Number of shared co-authors 0
The University of Texas M.D. Anderson Cancer Center
Career Start Year 1994
Number of shared co-authors 12
National Cancer Center
Career Start Year 1994
Number of shared co-authors 2
Taussig Cancer Institute, Cleveland Clinic
Career Start Year 1994
Number of shared co-authors 4
Meyer Cancer Center
Career Start Year 1990
Number of shared co-authors 8
Medical University of Innsbruck
Career Start Year 1990
Number of shared co-authors 1
Massachusetts General Hospital and Harvard Medical School
Career Start Year 1990
Number of shared co-authors 8
Kyorin University Faculty of Medicine
Career Start Year 1988
Number of shared co-authors 2
University Hospital and University of Zurich
Career Start Year 1987
Number of shared co-authors 17
University of California san francisco
Career Start Year 1987
Number of shared co-authors 12
University of Virginia Health System
Career Start Year 1987
Number of shared co-authors 3
Medical University of Vienna
Career Start Year 1987
Number of shared co-authors 2
Saitama Medical University International Medical Center
Career Start Year 1986
Number of shared co-authors 7
University of California san francisco
Career Start Year 1982
Number of shared co-authors 13
The University of Texas M.D. Anderson Cancer Center, American University of Beirut
Career Start Year 1979
Number of shared co-authors 10
Duke University Medical Center
Career Start Year 1978
Number of shared co-authors 3
University of Texas M.D. Anderson Cancer Center
Career Start Year 1974
Number of shared co-authors 17
Henry Ford Hospital
Career Start Year 1973
Number of shared co-authors 1
University of Virginia School of Medicine
Career Start Year 1966
Number of shared co-authors 16

Collaborators

The Geisel School of Medicine at Dartmouth
Co-authored papers 4
Princess Margaret Cancer Centre
Co-authored papers 3
David Geffen School of Medicine, University of California Los Angeles
Co-authored papers 3
Co-authored papers 3
Ontario Brain Institute
Co-authored papers 3
Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School
Co-authored papers 2
Brigham and Women's Hospital
Co-authored papers 2
Co-authored papers 2
Brain Tumor & Neuro-Oncology Cleveland Clinic Main Campus
Co-authored papers 2
Moores Cancer Center and Department of Medicine, University of California
Co-authored papers 2
University of California los angeles
Co-authored papers 1
University of California Los Angeles
Co-authored papers 1
Weill Cornell Medical College, New York Presbyterian Hospital
Co-authored papers 1
Co-authored papers 1
Northwestern University
Co-authored papers 1
University Health Network
Co-authored papers 1
Clinica Universidad de Navarra
Co-authored papers 1
University Hospitals Seidman Cancer Center, Case Western Reserve University
Co-authored papers 1
Karmanos Cancer Institute (KCI), Wayne State University
Co-authored papers 1
Moffit Cancer Center
Co-authored papers 1
Lehigh Valley Topper Cancer Institute
Co-authored papers 1
Thomas Jefferson University
Co-authored papers 1
The University of Texas MD Anderson Cancer Center
Co-authored papers 1
National Cancer Institute
Co-authored papers 1
DNATrix Inc.
Co-authored papers 1
University of Arkansas for Medical Sciences
Co-authored papers 1
Princess Margaret Cancer Centre, University Health Network and University of Toronto
Co-authored papers 1
Huntsman Cancer Institute, University of Utah
Co-authored papers 1
Northwestern University, Feinberg School of Medicine
Co-authored papers 1
Baylor University Medical Center
Co-authored papers 1